dc.contributor.author | Wormald, B | |
dc.contributor.author | Rodriguez-Manzano, J | |
dc.contributor.author | Moser, N | |
dc.contributor.author | Pennisi, I | |
dc.contributor.author | Ind, TEJ | |
dc.contributor.author | Vroobel, K | |
dc.contributor.author | Attygalle, A | |
dc.contributor.author | Georgiou, P | |
dc.contributor.author | deSouza, NM | |
dc.date.accessioned | 2022-06-01T11:57:25Z | |
dc.date.available | 2022-06-01T11:57:25Z | |
dc.date.issued | 2021-11-01 | |
dc.identifier.citation | Frontiers in oncology, 2021, 11 pp. 747614 - ? | |
dc.identifier.issn | 2234-943X | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5170 | |
dc.identifier.eissn | 2234-943X | |
dc.identifier.eissn | 2234-943X | |
dc.identifier.doi | 10.3389/fonc.2021.747614 | |
dc.identifier.doi | 10.3389/fonc.2021.747614 | |
dc.description.abstract | OBJECTIVE: To establish the sensitivity and specificity of a human papillomavirus (HPV) and tumor marker DNA/mRNA assay for detecting cervical cancer that is transferrable to a Lab-on-a-chip platform and determine its diagnostic benefit in early stage disease when used in conjunction with high-resolution endovaginal magnetic resonance imaging (MRI). METHODS: Forty-one patients (27 with Stage1 cervical cancer [Group1] and 14 non-cancer HPV negative controls [Group2]) had DNA and RNA extracted from cervical cytology swab samples. HPV16, HPV18, hTERT, TERC/GAPDH and MYC/GAPDH concentration was established using a loop mediated isothermal amplification (LAMP) assay. Thresholds for tumor marker detection for Group1 were set from Group2 analysis (any hTERT, TERC/GAPDH 3.12, MYC/GAPDH 0.155). Group 1 participants underwent endovaginal MRI. Sensitivity and specificity for cancer detection by LAMP and MRI individually and combined was documented by comparison to pathology. RESULTS: Sensitivity and specificity for cancer detection was 68.8% and 77.8% if any tumor marker was positive regardless of HPV status (scenario1), and 93.8% and 55.8% if tumor marker or HPV were positive (scenario 2). Adding endovaginal MRI improved specificity to 88.9% in scenario 1 (sensitivity 68.8%) and to 77.8%% in scenario2 (sensitivity 93.8%). CONCLUSION: Specificity for cervical cancer detection using a LAMP assay is superior with tumor markers; low sensitivity is improved by HPV detection. Accuracy for early stage cervical cancer detection is optimal using a spatially multiplexed tumor marker/HPV LAMP assay together with endovaginal MRI. | |
dc.format | Electronic-eCollection | |
dc.format.extent | 747614 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | FRONTIERS MEDIA SA | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.title | Loop-Mediated Isothermal Amplification Assay for Detecting Tumor Markers and Human Papillomavirus: Accuracy and Supplemental Diagnostic Value to Endovaginal MRI in Cervical Cancer. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-10-13 | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.3389/fonc.2021.747614 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.relation.isPartOf | Frontiers in oncology | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance | |
pubs.publication-status | Published | |
pubs.volume | 11 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Magnetic Resonance | |
dc.contributor.icrauthor | deSouza, Nandita | |